anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: This review aimed to compile an exhaustive list of all outcome measures and identify different characteristics of the outcomes reported in studies of intermittent claudication as the first step in developing a core outcome set for intermittent claudication.
METHOD: Medline and Embase were searched for all studies including individuals with intermittent claudication and reporting ≥1 outcome from January 2015 to August 2024. Abstract, full text screening and data extraction were performed by two investigators independently. All reported outcome measures were extracted verbatim and categorized by Dodd's domains (Core Outcome Measures in Effectiveness Trials registration: COMIC Study, 1590; https://www.comet-initiative.org/Studies/Details/1590).
RESULTS: 4985 studies were screened and 408 were included. A total of 541 unique outcomes across 25 Dodd's domains were identified. Ankle-brachial pressure index was the most frequently reported outcome. Among the 541 unique outcomes, 386 outcomes were only reported once. Only 38.9% of the studies exclusively included patients with intermittent claudication. Patient-reported outcomes were reported in 36.2% of studies. There were wide variations in the definition of commonly used outcome measures (for example, major adverse limb event and primary patency) across different studies.
CONCLUSION: There is substantial heterogeneity in reported outcomes in studies of intermittent claudication. Most reported outcomes are clinical/physiology oriented rather than patient centred. Development of a core outcome set for intermittent claudication is vital to improve and standardize reporting in future research.
Senescent cells contribute to tissue aging and underlie the pathology of chronic diseases. The benefits of eliminating senescent cells have been demonstrated in several disease models, and the efficacy of senolytic drugs is currently being tested in humans. Exercise training has been shown to reduce cellular senescence in several tissues; however, the mechanisms responsible remain unclear. We found that myocyte-derived factors significantly extended the replicative lifespan of fibroblasts, suggesting that myokines mediate the anti-senescence effects of exercise. A number of proteins within myocyte-derived factors were identified by mass spectrometry. Among these, pigment epithelium-derived factor (PEDF) exerted inhibitory effects on cellular senescence. Eight weeks of voluntary running increased Pedf levels in skeletal muscles and suppressed senescence markers in the lungs. The administration of PEDF reduced senescence markers in multiple tissues and attenuated the decline in respiratory function in the pulmonary emphysema mouse model. We also showed that blood levels of PEDF inversely correlated with the severity of COPD in patients. Collectively, these results strongly suggest that PEDF contributes to the beneficial effects of exercise, potentially suppressing cellular senescence and its associated pathologies.
As the involvement of the intestinal microbiota in the etiopathology of irritable bowel syndrome, subtype diarrhoea (IBS-D) is now increasingly recognised, a preliminary, quasi-experimental, before-after and prospective study was conducted on 28 patients to test the effect of a tannin-based supplement on the composition and activity of the microbiota, after 8 weeks of treatment. No statistically significant differences were found in α- or β-diversity. However, sparse Partial Least Squares Discriminant Analysis (sPLS-DA) and Boruta algorithm did reveal significant changes in the relative abundance of specific groups of bacteria, highlighting the involvement of recognized of IBS-D biomarkes, namely Blautia (adj p = 3.5 × 10-11), Eubacterium hallii group (adj p = 5.1 × 10-12) and Dorea (adj p = 1.8 × 10-18), which resulted significantly depleted by the treatment. The modulation of the composition of the gut microbiota had an impact also in the production of short chain fatty acids (SCFAs), which were modulated: acetate and butyrate (n.s. and p = 0.000143) increased while propionate and formate resulted to be significantly reduced (p = 0.00476 and p = 0.00011, respectively), following the supplementation. Finally, the sPLS analysis showed that the strongest association between faecal microbiome composition and clinical symptoms of IBS-D was given by Catenibacterium, which showed a positive correlation with evacuation-related symptoms. Such preliminary findings suggest that tannin supplementation could play an outstanding role in microbiota modulation in IBS-D patients, potentially improving their symptomatology, by selectively acting on the growth and the activity of specific groups of taxa.
INTRODUCTION: Community acquired bloodstream infection (CA-BSI) is positive blood culture obtained within 48 hours of hospital admission. Bloodstream infections need to be treated with antibiotics. Inappropriate choice of antibiotics will lead to antimicrobial resistance. This is an observational retrospective study to look at the antimicrobial resistance of organisms causing bloodstream infections in patients admitted to the medical wards in our centre. The aim of the study is to determine the appropriate choice of empirical antibiotics for suspected CA-BSI in our hospital.
MATERIALS AND METHODS: All patients admitted to medical wards with blood stream infection during the period January 2021 to June 2021 were enrolled. Identification of organisms and antimicrobial susceptibility testing were obtained. Information regarding the severity of the bacteremia was collected by assessing if the patient needed inotropes, mechanical ventilation or renal replacement therapy. Data on comorbidities which were the presence of end-stage renal failure, diabetic mellitus and immunosuppression were collected.
RESULTS: Total of 269 cases were screened. Out of these 104 communities acquired cases were included. The pathogens frequently isolated were gram negative organisms most commonly Escherichia coli (43%) and Klebsiella species (30%). Staphylococcus aureus accounts for the majority of gram-positive organisms. Only two out of 20 Staphylococcus aureus were methicillin resistant. Bulkholderia pseudomallei accounts for 7.8% cases. All Burkholderia pseudomallei isolates were sensitive to cotrimoxazole. Escherichia coli (46%) isolates demonstrated a higher resistance pattern to Augmentin compared to klebsiella species (17.4%). The overall mortality rate was 22%, with higher rates for those critically ill (39%). Patients with Enterobacteriaceae infection showed no difference in outcome between the groups of patients according to sensitivity to Augmentin and cefotaxime. These groups of patients who were critically ill did not demonstrate any significant difference in terms of resistance pattern to Augmentin (p = 0.3) and cefotaxime (p = 0.7). Patients who are aged 65 or older have a significantly more resistant pattern to Augmentin and cefotaxime.
CONCLUSION: Antibiogram serves as a guide for clinicians to choose appropriate choices of antibiotics based on local data. Empirical antibiotics of choice for patients with sepsis should be narrow-spectrum beta lactam/beta lactamase inhibitors. Broad spectrum beta lactam/beta lactamase inhibitors such as piperacillin tazobactam should be reserved for patients who are critically ill and elderly patients over 65 years. The antibiotics should be deescalated once the organisms and sensitivity of the antibiotics are known.
PURPOSE:To prepare a transparent compounded drug of vitamin B2 butyric acid ester for soft capsule, preservable extremely stably for a long period without forming precipitate, and having unparallelled high titer, by dissolving vitamin B2 butyric acid ester in free cholesterol. CONSTITUTION:The titled drug can be prepared by dissolving vitamin B2 butyric acid ester in free cholesterol. Although vitamin B2 butyric acid ester has poor solubility in oils used as a drug component, the solubility can be improved remarkably by the addition of a compound having phenolic hydroxyl group, especially free cholesterol. A soft capsule of vitamin B2 butyric acid ester having unparallelled high titer, e.g. about 30mg/cap can be prepared by this process. It has no irritation to the oral mucosa and digestive tracts, is free from crystallization even at a low temperature, and can be stored extremely stably for a long period.
Use of cells (A) from medullar or extramedullar white adipose tissue to prepare a composition for total or partial reconstruction of a functional vascular network. (A) are able to form homogeneous subpopulations that express at least one of the surface antigens CD13 and HLA ABC. An independent claim is also included for a process for culturing (A). ACTIVITY : Vasotropic; Vulnerary. No details of tests for these activities are given. MECHANISM OF ACTION : Induction of angiogenesis.
The invention discloses a pidotimod arginine salt and a preparation thereof. The pidotimod arginine salt can be used to cure: 1. repeated outbreak upper and lower respiratory tract infections (pharyngitis, trachitis, bronchitis and tonsillitis); 2. repeated ear-nose-throat infections (nasitis, nasosinusitis and otitis); 3. urinary system infections; 4. gynecologic infections; 5. cellular immune hypofunction of clinical patients after chemotherapy; 6. specific and non-specific immunodeficiency diseases such as cancers, and the like. The pidotimod arginine salt can reduce the times of acute attacks, shorten the course of diseases and relieve the degree of attacks; and the pidotimod arginine salt can be used as an auxiliary antibiotic for curing acute infections. After pidotimod and arginine react with each other in water or ethanol (but not limited to the solvents), the obtained product is concentrated and dried, or is added with insoluble organic solvent for crystallization or is lyophilized to obtain the pidotimod arginine salt. When pharmaceutically acceptable auxiliary materials are added in the pidotimod arginine salt, pharmaceutically acceptable preparations, including but not limited to tablets, capsules, injections and the like can be prepared. The pidotimod arginine salt can be made into infusions for intravenous injection, and can be added into glucose with content of 5 percent or sodium chloride injection with content of 0.9 percent to prepare injections, solvent-crystallized packed powder injections and lyophilized powder injections. The solubility of the pidotimod arginine salt in water is high and the stability of the pidotimod is improved. The pH value of the injections made of the pidotimod arginine salt is more close to the pH value of the human body.
The article "Differential DNA Methylation Associated with Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Systematic Review" by Tomasz Klepinowski et al. offers an in-depth analysis of the relationship between DNA methylation and delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH). By systematically reviewing databases like PubMed, MEDLINE, Scopus, and Web of Science, the authors identify key genes, including ITPR3, HAMP, INSR, and CDHR5, as potential biomarkers for early DCI diagnosis. Their meticulous adherence to PRISMA guidelines and the STROBE statement for quality assessment enhances the study's credibility. However, the review could be improved by discussing methodological variability, statistical power, and the functional relevance of identified CpG sites. Additional sections on mechanistic pathways, integration with other omics data, clinical translation, and ethical considerations would further strengthen the review, providing a more comprehensive understanding of epigenetic factors in DCI and paving the way for future therapeutic interventions.
Wound healing following skin tumour surgery still remains a major challenge. To address this issue, polysaccharide-loaded nanofibrous mats have been engineered as skin patches on the wound site to improve wound healing while simultaneously eliminating residual cancer cells which may cause cancer relapse. The marine derived polysaccharides kappa-carrageenan (KCG) and fucoidan (FUC) were blended with polydioxanone (PDX) nanofibers due to their inherent anti-cancer activity conferred by the sulphate groups as well as their immunomodulatory properties which can reduce inflammation resulting in accelerated wound healing. KCG and FUC were released sustainably from the blend nanofibers via the Korsmeyer-Peppas kinetics. MTT assays, live/dead staining and SEM images demonstrated the toxicity of KCG and FUC towards skin cancer MP 41 cells. In addition, MP 41 cells showed reduced metastatic potential when grown on KCG or FUC containing mats. Both KCG and FUC were non- cytotoxic to healthy L 929 fibroblast cells. In vivo studies on healthy Wistar rats confirmed the non-toxicity of the nanofibrous patches as well as their improved and scarless wound healing potential. In vivo studies on tumour xenograft model further showed a reduction of 7.15 % in tumour volume in only 4 days following application of the transdermal patch.
The proposed study aims to describe adaptation and dyadic adjustment in unaffected BRCA1/2 carriers and their partners. It is not fully understood how women and their partners adapt to highrisk status over time, nor how different aspects of living at risk relate to this process. Neither psychological adaptation nor dyadic adjustment has been systematically measured in this population. This study is informed by Lazarus \& Folkman s Transactional Model of Stress and Coping and modifications made to this model for use in studying dyadic relationships. A crosssectional research design will quantitatively explore the relationships between the appraisals and timing of risk-related stressors, dyadic coping, and the outcomes of adaptation and dyadic adjustment. Participants will be recruited from hereditary breast and ovarian cancer (HBOC) support groups, website postings, listservs, and clinic patient lists. They will have the option of completing either a paper or online version of the survey.
PURPOSE: To obtain a new compd. which has an excellent antithrombic activity, resistance against enzyme and tolerance and which is useful as a therapeutic drug or diagnostic drug of thrombosis.  
     CONSTITUTION: This compd. is expressed by the formula, wherein R' is naphthyl, chroman, etc.; R 1  is H, ≤4C alkyl, etc.; R 2 , R 3  are ≤4C alkyl or R 2  and R 3  form with the N atom an R- or S-structure ring. The compd. is, for example, β-naphthylsulfonyl-azaglycyl-D-P-amidinophenylalanylpiperidide. This compd. is obtd. by coupling BOC-cyanophenylalanine with a cyclic amine such as piperidine, successively coupling a P-nitrophenylester of a protected azamino acid and sulfonylchloride such as β-naphthylsulfonylchloride to the obtd. product to obtain a cyanophenylalanine deriv., then treating the deriv. with hydrogen sulfide in triethylamine/pyridine to produce a thioamide, methylating the thioamide, and then treating the obtd. thioimide acid methyl with an ammonium compd. in methanol. 
     COPYRIGHT: (C)1993,JPO
Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
A botanical composition for soothing irritated skin and method of producing the composition. The composition includes 90-97% by weight aloe juice; 1-5% by weight grapefruit seed and pulp extract; and 1-5% by weight vegetable glycerine. The aloe juice, grapefruit seed and pulp extract and vegetable glycerine are mixed together to form a liquid mixture for application to and covering the irritated skin. The grapefruit seed and pulp extract preferably has a pH of 3. A fragrance may be added to the composition to provide a desired odor to the composition and oils may be added to the composition for use in hydrating the irritated skin on which the composition is applied. The composition is stored in a spray bottle for creating a mist of the composition when applying the composition to the irritated skin.
This research will be completed at Mount Sinai Hospital. All participants will be identified from Mount Sinai Hospital records of infants born at MSH and/or cared for in the Mount Sinai NICU on or after January 1, 2011, at full term or preterm. The study team will contact the parents of eligible potential participants by telephone to explain the study and ask if the parent will consent to their child's participation. If the parent agrees, we will make an appointment for the child to come to Mount Sinai for the evaluation using the Bayley-III. The parents will be mailed the study consent form, a fact sheet with information about the study, and the CBCL to complete before they bring their child to their appointment. Mount Sinai records from the birth hospitalization will be reviewed for the birth history and medical comorbidities. Mount Sinai medical records of the mother's obstetric care will also be accessed to obtain medical history from the pregnancy. If a participating child has received outpatient care at Mount Sinai, the investigators will access their record in Epic to obtain scores from previous developmental assessments and records of medical comorbidities. If they have not attended the Mount Sinai clinic, but have received outpatient care elsewhere, the parents will be asked to provide contact information for their pediatrician, and for permission to obtain their child's records.
INTRODUCTION: The occurrence of lung ischemia-reperfusion injury (LIRI) after lung transplantation results in primary graft dysfunction (PGD) in more than 50% of cases, which seriously affects the prognosis of recipients. Currently, donor lung protection is the focus of research on improving graft survival in lung transplant recipients. Dexmedetomidine (Dex) is a widely used general anesthesia adjuvant in clinical practice to alleviate ischemia-reperfusion injury in the lungs, liver, heart, kidneys, and brain. However, intravenous infusion of Dex can cause negative effects on the cardiovascular system. Inhaling nebulized Dex can directly act on the alveolar tissue and alleviate its cardiovascular inhibitory effect by reducing drug intake. This study aimed to investigate the effect of donor nebulized Dex inhalation on LIRI after lung transplantation in rats.
METHODS: We randomly divided the male Sprague-Dawley rats into donor rats and recipient rats, and allowed the donor rats to inhale nebulized Dex or physiological saline 15 min before surgery. The donor lung was refrigerated for 8 h before each single-lung transplant. After 2 h of reperfusion of the transplanted lung, serum and transplanted lung tissue were collected. The wet-to-dry weight ratio of the lung tissue was measured, arterial blood gas was detected, and histopathology changes, oxidative stress, inflammatory reactions, and apoptosis were evaluated.
RESULTS: Pretransplant inhalation of Dex through the donor's lung reduced the injury of the transplanted lung, increased the levels of malondialdehyde and myeloperoxidase, and decreased the levels of superoxide dismutase and glutathione in the lung tissue. Moreover, nebulized Dex inhalation of the donor lung inhibited LIRI-induced tumor necrosis factor-α, interleukin-6, and inducible nitric oxide synthase expression and also suppressed nuclear factor kappa B phosphorylation. Nebulized Dex inhalation reduced the rate of cell apoptosis in the transplanted lung tissue by inhibiting the upregulation of Bax, downregulation of Bcl-2, and increase in caspase-3 lysis caused by LIRI.
CONCLUSION: Inhalation of atomized Dex is a potential donor lung protection strategy, which can be used to reduce LIRI after lung transplantation and may be helpful to improve the occurrence of PGD and prognosis of lung transplant recipients.
FIELD: medicine; pharmaceutics. ^ SUBSTANCE: invention concerns a pharmaceutical composition of vinflunine in the form of a stable and sterile aqueous solution of water-soluble vinflunine salt with concentration of the main vinflunine from 1 to 50 mg/ml, which pH value makes from 3 to 4. The composition does not contain any preservatives. The invention also concerns a way of reception of the specified composition and its application as a medical product for parenteral administration at cancer treatment. ^ EFFECT: invention provides a water pharmaceutical vinflunine composition for the injections, possessing stability within 36 months under the temperature of 5C 3C. ^ 13 cl, 1 dwg, 6 tbl, 2 ex
EUS would be performed with a curvilinear echoendoscope based on protocol described in our prior study. Because EUS-guided glue injection can be applied to both EV and GV and is less technically demanding than coiling or the combination approach, it is chosen as the EUS guided intervention in our study. The target EV or GV size will be measured by the caliper function on the EUS machine. After confirmation of blood flow in the target varix by Doppler, EUS-guided glue injection would be performed for EV or GV ≥ 3mm in diameter using a standard 19G needle. Each injection will contain a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol. Flow obliteration in the treated varix will be confirmed on EUS Doppler. If blood flow is still observed on Doppler after the first injection, additional injection of glue-lipiodol mixture would be repeated (up to 4 doses) until flow obliteration is achieved.
The present invention relates to: a pharmaceutical composition which is for preventing or treating diabetic skin diseases, and which comprises, as an active ingredient, an exosome derived from a thrombin-treated stem cell; a pharmaceutical formulation containing said composition; and a method for manufacturing the same. In the present invention, the exosome isolated from a thrombin-treated stem cell has been found to have an excellent effect on the recovery of diabetic animal models from diabetic dermatopathy. In addition, since exosome-based therapeutics are cell-free formulations and thus do not include DNA, such therapeutics have a low risk of cancer and are free of cell surface antigens. Accordingly, exosome-based therapeutics do not have the issue of transplant rejection and are thus safe. Moreover, being separation materials rather than cells, exosome-based therapeutics can be developed as off-the-shelf drugs, and thus reduce manufacturing costs. Accordingly, the exosome derived from a thrombin-treated stem cell according to the present invention can be developed as a therapeutic agent for various intractable chronic skin diseases that can be caused by diabetes, and furthermore, is expected to be useful for application to fields related to skin regeneration.
Ideally 71 patients with wounds at risk of infection (W.A.R. Score ≥ 3) to be included.
The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.